ATE490787T1 - Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion - Google Patents

Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Info

Publication number
ATE490787T1
ATE490787T1 AT04747833T AT04747833T ATE490787T1 AT E490787 T1 ATE490787 T1 AT E490787T1 AT 04747833 T AT04747833 T AT 04747833T AT 04747833 T AT04747833 T AT 04747833T AT E490787 T1 ATE490787 T1 AT E490787T1
Authority
AT
Austria
Prior art keywords
igm
production
quantifying
transformed cells
chain
Prior art date
Application number
AT04747833T
Other languages
English (en)
Inventor
Reiko Irie
Hiroyuki Tsunoda
Tomoyuki Igawa
Yasuo Sekimori
Masayuki Tsuchiya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE490787T1 publication Critical patent/ATE490787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04747833T 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion ATE490787T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48733303P 2003-07-15 2003-07-15
PCT/JP2004/010444 WO2005005636A1 (ja) 2003-07-15 2004-07-15 形質転換細胞によるIｇMの産生とその定量方法

Publications (1)

Publication Number Publication Date
ATE490787T1 true ATE490787T1 (de) 2010-12-15

Family

ID=34062150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04747833T ATE490787T1 (de) 2003-07-15 2004-07-15 Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Country Status (9)

Country Link
US (2) US7709615B2 (de)
EP (2) EP1652925B1 (de)
JP (1) JP5452835B2 (de)
AT (1) ATE490787T1 (de)
AU (1) AU2004256354B2 (de)
CA (1) CA2532966C (de)
DE (1) DE602004030451D1 (de)
TW (1) TW200510532A (de)
WO (1) WO2005005636A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030451D1 (de) * 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
EP1686137A4 (de) * 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung von proteinlösungen
EP1688432B1 (de) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Stabilisierte lösung mit hoher igm-konzentration
EP1835022B1 (de) 2005-01-05 2015-02-11 Chugai Seiyaku Kabushiki Kaisha Zellkulturverfahren und dessen nutzung
JP2008547035A (ja) * 2005-06-27 2008-12-25 インヴィトロジェン コーポレーション ネイティブゲル電気泳動用の液体状タンパク質マーカー
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
US8852585B2 (en) * 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
SG185302A1 (en) 2007-10-15 2012-11-29 Chugai Pharmaceutical Co Ltd Method for production of antibody
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102164962B (zh) 2008-06-30 2014-05-28 诺福泰克公司 抗gd2抗体和方法及其相关应用
JP5232241B2 (ja) * 2008-10-31 2013-07-10 独立行政法人科学技術振興機構 ヘルパーｔ細胞の選択的機能制御法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
HRP20250713T8 (hr) 2011-09-01 2025-10-24 Chugai Seiyaku Kabushiki Kaisha Postupak priprave pripravka koji sadrži visoko koncentrirana protutijela ultrafiltriranjem
CN108285483B (zh) * 2012-04-17 2022-04-26 梅奥医学教育和研究基金会 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
EP2925783B1 (de) * 2012-11-30 2020-07-29 Katinger GmbH Rekombinanter humaner igm antikoerper effektiv gegen krebszellen
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
EP3185004A4 (de) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (de) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20-bindende moleküle und verwendungen davon
WO2016154593A1 (en) * 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
EP3356401B1 (de) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Bindungsmoleküle mit modifizierter j-kette
EP3355913B1 (de) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Bindungsmoleküle mit modifizierter j-kette
US10572893B2 (en) 2016-06-16 2020-02-25 International Business Machines Corporation Discovering and interacting with proximate automobiles
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN115636142A (zh) 2018-05-28 2023-01-24 中外制药株式会社 填充喷嘴
EP4003333A4 (de) 2019-07-31 2023-11-01 The Wistar Institute for Anatomy and Biology Multivalente dna-antikörperkonstrukte und ihre verwendung
EP4139362A2 (de) * 2020-04-22 2023-03-01 IGM Biosciences Inc. Multimere pd-1-agonist-bindungsmoleküle
EP4297786A4 (de) * 2021-02-23 2025-01-22 Pandion Operations, Inc. Pd-1-antikörper, polypeptide und verwendungen davon
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
ES2045027T3 (es) 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
US5157113A (en) * 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US6238891B1 (en) * 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
CA1312030C (en) 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
JP2501116B2 (ja) 1988-03-05 1996-05-29 日本電信電話株式会社 巡回制御形回線交換方法
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
GB9010944D0 (en) 1990-05-16 1990-07-04 Central Blood Lab Authority Chemical compounds
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
JPH05192181A (ja) 1990-12-18 1993-08-03 Ishihara Sangyo Kaisha Ltd ヒトモノクローナル抗体
EP0492409A1 (de) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Menschlicher monoklonaler Antikörper
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
SG47766A1 (en) * 1991-03-12 1998-04-17 Biogen Inc CD2-binding domain of lymphocyte function associated antigen 3
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JPH04360696A (ja) * 1991-06-06 1992-12-14 Sumitomo Chem Co Ltd 新規なヒトｂリンパ細胞株を宿主として産生された組み換えヒト抗体
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP3565572B2 (ja) 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
JPH06178689A (ja) * 1992-12-11 1994-06-28 Mitsui Toatsu Chem Inc Ｉ型緑膿菌を抗原とするヒト抗体をコードする遺伝子
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
JPH09127112A (ja) 1995-10-30 1997-05-16 Dainabotsuto Kk 修飾ＩｇＭ免疫学的測定試薬
JPH09127114A (ja) 1995-11-01 1997-05-16 Dainabotsuto Kk 免疫学的測定用安定化ＩｇＭ試薬
JP2000516470A (ja) * 1996-08-16 2000-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
WO1999036105A2 (en) 1998-01-16 1999-07-22 Mca Development B.V. USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP2002504342A (ja) * 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
JP2000154149A (ja) * 1998-09-18 2000-06-06 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体含有抗リウマチ剤
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
WO2001023431A1 (fr) 1999-09-30 2001-04-05 Kyowa Hakko Kogyo Co., Ltd. Derives d'anticorps contre le ganglioside gm2
WO2001033957A1 (en) * 1999-11-05 2001-05-17 Kyowa Hakko Kogyo Co., Ltd. Transgenic non-human mammals for monitoring change in calcium ion concentration in cells
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6723606B2 (en) 2000-06-29 2004-04-20 California Institute Of Technology Aerosol process for fabricating discontinuous floating gate microelectronic devices
AU2001277696A1 (en) * 2000-08-01 2002-02-13 Kyowa Hakko Kogyo Co. Ltd. Novel physiologically active peptide and use thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2003128576A (ja) * 2001-10-25 2003-05-08 Taisho Pharmaceut Co Ltd エンドトキシン誘発性疾患治療薬
WO2003046162A2 (en) 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
DE10328295B4 (de) 2003-06-23 2007-11-22 Endress + Hauser Gmbh + Co. Kg Verfahren und entsprechende Vorrichtung zum Schweißen von Bauteilen eines Feldgerätes
WO2005003557A1 (en) 2003-06-25 2005-01-13 Design Net Engineering, Llc Laser propulsion thruster
DE602004030451D1 (de) * 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
EP1688432B1 (de) * 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Stabilisierte lösung mit hoher igm-konzentration
EP1686137A4 (de) 2003-10-09 2009-10-28 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung von proteinlösungen

Also Published As

Publication number Publication date
AU2004256354A1 (en) 2005-01-20
WO2005005636A1 (ja) 2005-01-20
US8257703B2 (en) 2012-09-04
CA2532966A1 (en) 2005-01-20
AU2004256354B2 (en) 2011-07-07
JP5452835B2 (ja) 2014-03-26
US20070154469A1 (en) 2007-07-05
US20100172899A1 (en) 2010-07-08
EP1652925B1 (de) 2010-12-08
EP2204190A1 (de) 2010-07-07
EP1652925A1 (de) 2006-05-03
TWI342336B (de) 2011-05-21
TW200510532A (en) 2005-03-16
US7709615B2 (en) 2010-05-04
DE602004030451D1 (de) 2011-01-20
EP1652925A4 (de) 2007-07-04
JPWO2005005636A1 (ja) 2006-08-24
CA2532966C (en) 2012-12-04

Similar Documents

Publication Publication Date Title
ATE490787T1 (de) Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
HRP20130750T1 (hr) Postupak identifikacije molekula za vezanje koje mogu neutralizirati virus bjesnoä†e
EP1427445A4 (de) Verfahren zur reifung von plasmacytoiden dendritischen zellen unter verwendung von die immunantwort modifizierenden molekülen
WO2004022714A3 (en) Organic species that facilitate charge transfer to or from nanostructures
ATE340174T1 (de) Verfahren zur umwandlung von dihidroisoxazol derivate in gamma-hydroxaminsäurederivate, z.b monatins
DE60321625D1 (de) Verfahren zur Herstellung von Acrylsäure
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
DE60321626D1 (de) Verfahren zur Herstellung von Acrylsäure
ATE457974T1 (de) Verfahren zur herstellung von phenylmalonsäure- dinitrilen
ATE458044T1 (de) Verfahren zur nukleinsäureamplifikation
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE60331111D1 (de) Verfahren zur Herstellung von martensitaushärtendem Stahl
ATE336464T1 (de) Verfahren zur aufreinigung von blausäure
DE60331043D1 (de) Verfahren zur entfernung von dithiogruppen aus polymerkettenenden
WO2007044066A3 (en) Methods for normalizing and for identifying small nucleic acids
ATE290076T1 (de) Ein verfahren zur trennung und reinigung von rna
DE60200012D1 (de) Verfahren zur Herstellung von Luftreifen
DE60315741D1 (de) Verfahren zur Herstellung von Acrylsäure
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
ATE548395T1 (de) Verfahren zur herstellung von polyolefinen in suspension
DE502004011774D1 (de) Verfahren zur herstellung von leder
DE50313133D1 (de) Verfahren zur erkennung von reifeneigenschaften
DE60336986D1 (de) Verfahren zur herstellung von biarylverbindungen
ATE420168T1 (de) Verfahren zur herstellung von extrachromosomalen nukleinsäuremolekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties